Emtricitabine/tenofovir alafenamide (Descovy®)

Assessment Status Rapid review complete
Drug Emtricitabine/tenofovir alafenamide
Brand Descovy®
Indication In combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1
Assessment Process
Rapid review commissioned 26/04/2016
Rapid review completed 26/04/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.

The HSE has approved reimbursement following confidential price negotiations.